India's Medicamen Biotech rises on facility getting EU GMP certification
12/09/2024 04:50
** Shares of Medicamen Biotech MEBI.NS rise 9.3% to 484
rupees, on track for best day since July 3
** Pharma co's facility in Indian state of Rajasthan got EU
GMP certification from National Organisation for Medicines,
Greece
** Stock on track to rise in fourth straight session, gained
16% in this time
** Stock down ~20% YTD after falling for two straight years
(Reporting by Varun Vyas in Bengaluru)
((varunvyas.hebbalalu@thomsonreuters.com))
Recent news on Medicamen Biotech
See all newsBrief: Medicamen Biotech Recommends Final Dividend Of 1 Rupee Per Share For FY Ended March 31, 2026
Brief: Medicamen Biotech Gets EU Approval For Registration Of “Paracetamol” From Denmark With XGX Pharma
India's Medicamen Biotech gains on US FDA nod for blood cancer drug
Brief: Medicamen Biotech Approves Allotment Of Shares, Warrants
India's Medicamen Biotech rises after deal with Denmark's XGX Pharma